Immunocan Secures RMB250 Million Series A Funding to Accelerate Gene-Edited Animal Platforms and AI-Driven Antibody Discovery
Shanghai-based Immunocan, a burgeoning biopharmaceutical company at the forefront of antibody discovery and gene-editing technologies, has successfully closed a RMB250 million (approximately $34.5 million USD) Series A funding round. This…
The Trump-Netanyahu War Against Iran Triggers Economic Crisis, Greenpeace East Asia Urges South Korea to Accelerate Renewable Energy Transition
SEOUL – A burgeoning conflict initiated by the United States and Israel against Iran has plunged the global economy into a severe crisis, echoing and surpassing the oil shocks of…







